Janssen, Bayer Lose Preemption Bids As Xarelto Trial Nears

By Cara Salvatore (April 13, 2017, 8:52 PM EDT) -- Days before a first bellwether trial begins in multidistrict litigation over the alleged dangers of blood thinner Xarelto, a Louisiana federal judge on Wednesday refused to drop some claims against Bayer AG and Janssen Pharmaceuticals Inc., saying they can't necessarily blame U.S. Food and Drug Administration red tape for their lack of label updates or for any noncompliance with Louisiana law.

U.S. District Judge Eldon Fallon denied two motions for partial summary judgment, both filed on Jan. 20, that cited federal preemption as a defense to claims over alleged Xarelto misdosing and a label with allegedly inadequate warnings. Patients in the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!